Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving combination chemotherapy together with
alemtuzumab works in treating patients with relapsed or refractory acute lymphoblastic
leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as
alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer
cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Giving combination chemotherapy together with alemtuzumab may kill more
cancer cells.